| Previous Close | 9.38 |
| Open | 10.12 |
| Volume | 505,913 |
| Avg. Volume (3M) | 149,645 |
| Market Cap | 2,921,482,240 |
| Price / Earnings (Forward) | 42.37 |
| Price / Sales | 4.14 |
| 52 Weeks Range |
| Profit Margin | 16.42% |
| Operating Margin (TTM) | 7.97% |
| Diluted EPS (TTM) | 0.370 |
| Quarterly Revenue Growth (YOY) | 260.00% |
| Quarterly Earnings Growth (YOY) | -65.50% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -148.89 M |
| Levered Free Cash Flow (TTM) | -216.76 M |
| Return on Assets (TTM) | 7.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Alvotech | Bearish | Bearish |
AIStockmoo Score
-1.3
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.25 |
|
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 63.44% |
| % Held by Institutions | 6.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lodbrok Capital Llp | 31 Dec 2024 | 181,587 |
| Oaktree Fund Advisors, Llc | 31 Dec 2024 | 116,294 |
| 52 Weeks Range | ||
| Median | 14.00 (44.63%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 18 Jul 2025 | 14.00 (44.63%) | Buy | 8.63 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |